Compare Phillips 66 (PSX) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Phillips 66 vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Phillips 66 trades at $278.52 (market cap $112.36B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.75 (market cap $58.74B). The key difference: Phillips 66 is the larger of the two by market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.33%). Which is the better fit depends on your goals — on Pluang, investors hold Phillips 66 for 62 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| PSX | TAK | |
|---|---|---|
Market Cap | $112.36B | $58.74B |
Volume | 2,374,751 | 3,110,994 |
Sector | Energy | Health |
52-Week High | $281.60 | $19.05 |
52-Week Low | $126.76 | $13.23 |
Typical Hold Time | 62 Days | 1 Days |
Enterprise Value | $128.83B | $86.65B |
Dividend Yield | 1.8% | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Phillips 66 (PSX) trades at $283.31, up 4.3% with strong technical momentum and bullish moving average signals. The stock shows solid fundamentals with a P/E of 16.07, ROE of 24.02%, and consistent earnings beats in recent quarters. Recent news highlights structural refining advantages and AI implementation for operational efficiency, while analyst consensus remains positive with 54% buy ratings.
PSX presents a compelling investment case with strong profitability metrics and positive earnings momentum, though investors face risks from volatile energy markets and potential policy changes affecting diesel exports. The current price sits near consensus targets, suggesting balanced near-term upside potential with structural refining strengths supporting long-term value.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
